Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.
Animab BV, a biotechnology company, develops monoclonal antibodies for livestock. It develops mimic secretory IgA, a type of natural antibody passed through colostrum and milk to protect nursing animals. The company will help swine producers with antibiotics for the control of gastrointestinal pathogens. Animab BV was incorporated in 2020 and is based in Ghent, Belgium.
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
ExeVir Bio BV is a Belgium-based biotechnology company established in 2020, focused on developing single-domain antibody therapies to combat viral infections. The company utilizes a llama-derived antibody technology platform, specifically the VHH technology, to create robust antiviral treatments that offer broad protection against coronaviruses, including SARS-CoV-2. ExeVir's lead candidate, VHH72-FC, targets a conserved region on the virus's spike protein essential for cellular entry. This innovative approach not only aims to provide effective treatment and prevention strategies for viral infections but also enables rapid development of drug candidates in response to emerging health threats, ensuring stability and cost-effectiveness for global access. ExeVir Bio's therapies are designed to reduce viral load and inflammation, thereby supporting immune responses and protecting vulnerable populations, including healthcare workers and individuals with co-morbidities.
Orionis Biosciences operates in the healthcare industry focusing on the biotechnology business and innovation. The company is an early-stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical needs – with an initial internal focus in oncology and immunotherapies. Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients with Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two primary drug discovery programs aimed at identifying selective HDAC6 inhibitors and GABABR1a agonists. These compounds are designed to offer neuroprotection against nerve degeneration and to promote the repair of peripheral myelin. Through its research and development efforts, Augustine Therapeutics aims to enhance the quality of life for patients afflicted with these challenging neurological conditions.
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.
OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.
Orionis Biosciences operates in the healthcare industry focusing on the biotechnology business and innovation. The company is an early-stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical needs – with an initial internal focus in oncology and immunotherapies. Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.